{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-034975","form_type":"8-K","ticker":"ADCT","cik":"0001771910","company_name":"ADC Therapeutics SA","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.475280+00:00","generated_at":"2026-05-31T12:22:53.802289+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ADC Therapeutics Q2 2024: ZYNLONTA $17M (−5% QoQ), net loss $36.5M, cash extended to mid-2026","bullets":["ZYNLONTA net sales $17.0M in Q2 2024 (−5% QoQ, −11% YoY); commercial profitability achieved.","Net loss $36.5M ($0.38/sh) vs $48.9M ($0.60/sh) in Q2 2023; adjusted net loss $24.4M ($0.25/sh).","Cash $300.1M after $97.4M May 2024 offering; runway extended into mid-2026.","LOTIS-5 Phase 3 IDMC recommended continue; full enrollment expected before year-end 2024.","LOTIS-7 dose expansion on track; safety/efficacy data expected year-end 2024, mature data H1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-034975","json":"https://secwatch.observer/filing/0001628280-24-034975.json","markdown":"https://secwatch.observer/filing/0001628280-24-034975.md","text":"https://secwatch.observer/filing/0001628280-24-034975.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1771910/000162828024034975/0001628280-24-034975-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1771910/000162828024034975/adc-20240806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:22:53.802289+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}